BioInvent International AB (BINV.ST) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Sweden · ISIN SE0015244520
BioInvent International AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 44.69 m SEK | 226.50 m SEK |
| Gross profit | 44.69 m SEK | 226.50 m SEK |
| Operating income | -471.06 m SEK | -351.39 m SEK |
| EBIT | -428.69 m SEK | -351.39 m SEK |
| Net income | -429.38 m SEK | -332.86 m SEK |
| Diluted EPS – continuing operations | -6.53 SEK | -5.06 SEK |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
More stocks
- Western Uranium & Vanadium Corp. (WSTRF)
- Eva Live Inc (GOAI)
- Crisp Momentum Inc. (CRSF)
- Karbon-X Corp. (KARX)
- ATOSSA THERAPEUTICS, INC. (ATOS)
- PetVivo Holdings, Inc. (PETV)
- Sun Pacific Holding Corp. (SNPW)
- SolarMax Technology, Inc. (SMXT)
- REED'S, INC. (REED)
- AYTU BIOPHARMA, INC (AYTU)
- FULL HOUSE RESORTS INC (FLL)
- SRX Global Inc. (SRXH)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.